銀行貸款 小額借貸 線上貸款 汽車貸款 手機貸 瘋正妹 橘子影城 古蹟交流社 東森新聞手機板 東森新聞 港書館 super娛樂城 金鈦城娛樂城 信用版娛樂城 贏家娛樂城 WG娛樂城
Retail-focused jewellery brand PNGS Reva Diamond Jewellery is launching its IPO for public subscription today, 24 February 2026. Ahead of the IPO opening, the company raised ?171 crore from anchor investors on 23 February 2026.?
Issue Type: The IPO is a book-build issue of ?380 crores, consisting entirely of a fresh issue of 0.98 crore shares.
Lot Size: 32 shares
Price Band: ?367-?386 per share
Minimum Investment: ?12,352 (for retail investors)
IPO Closing Date: February 26, 2026
Allotment Date: The basis of allotment will be finalised by February 27, 2026.
Listing Date: The tentative listing date on BSE and NSE is March 4, 2026.?
Book Running Lead Manager: Smart Horizon Capital Advisors Private Limited
Registrar: Bigshare Services Private Limited
[24-February-2026 11:24:00 hrs]
|
Investor Category |
Subscription (Times) |
|
Qualified Institutional Buyers (QIBs) |
0.00 |
|
Non-Institutional Investors |
0.01 |
|
Retail Individual Investors (RIIs) |
0.18 |
|
Employees |
1.66 |
|
Total |
0.04 |
The net proceeds from the fresh issue will be used to fund the expenses towards the following objectives:
Explore other Upcoming IPOs on BSE and NSE.
As per media reports, the Grey Market Premium (GMP) of PNGS Reva Diamond Jewellery is reported at ?17 over the IPO price.?
PNGS Reva Diamond Jewellery specialises in diamond-studded ornaments crafted in gold and platinum. The brand offers an extensive portfolio that includes jewellery embedded with diamonds, precious stones, and semi-precious gemstones, along with a curated range of plain platinum products such as rings, chains, and bracelets.
The company’s revenue from operations has fluctuated over the past three fiscal years, decreasing from ?198.85 crore in FY 2023 to ?195.63 crore in FY 2024 and subsequently increasing to ?258.18 crore in FY 2025, reflecting a CAGR of 13.95%.
Disclaimer: This news is solely for educational purposes. The securities/investments quoted here are not recommendatory.
To read the RA disclaimer, please click here.